Eckert & Ziegler has developed a unique, stable and reliable method to produce a highly pure form of Lu-177 n.c.a. which will be used by Alpha-9 for the clinical trials of its therapeutic candidates for solid and hematologic malignancies.

Lutetium-177 is a beta emitting radioisotope that can be linked to a variety of tumor specific drugs which then incorporates the radiating element of the radioisotope into the tumor cells.

“The supply contract with Canada-based Alpha-9 further underlines our outstanding expertise in supplying isotopes to the pharmaceutical industry. With production sites in Europe, Asia, and North America, we are excellently positioned to meet the growing demand for relevant isotopes and the associated development and production services," explained Dr. Harald Hasselmann, Executive Director and responsible for the Medical segment of Eckert & Ziegler. “Our recently concluded joint venture with Atom Mines LLC provides us with excellent access to the scarce and indispensable precursor ytterbium-176, enabling us to supply lutetium-177 n.c.a. in highest purity and reliably to pharmaceutical customers worldwide.”

Alpha-9 is committed to developing its portfolio and exploring potential therapies to help patients. Alpha-9 is looking forward to its partnership with Eckert & Ziegler and the potential that this partnership creates to advance radioligand therapy.

Targeted radionuclide therapy with Lutetium-177, currently under late-stage clinical development for several types of cancer, may provide a valuable alternative treatment option in the field of precision oncology.

About Alpha-9 Theranostics
Alpha-9 Theranostics is a clinical stage, radiopharmaceutical company developing imaging and therapeutic molecules for solid and hematologic malignancies. Using proprietary technology and the Company’s expertise, these differentiated molecules have the potential to meaningfully extend patients’ lives with favorable safety profiles. www.alpha9tx.com